Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
AffiliationCRUK Department of Medical Oncology, University of Manchester, Christie Hospital, Manchester, UK. email@example.com
MetadataShow full item record
AbstractEndocrine therapies act by either blocking or downregulating the oestrogen receptor or by reducing oestrogen concentrations around and within the cancer cell. In postmenopausal women, oestrogen suppression is achieved by inhibition of the enzyme aromatase by aromatase inhibitors (AIs). Modern AIs (anastrozole, letrozole and exemestane) are more potent than earlier ones and suppress oestradiol levels in plasma to virtually undetectable concentrations. Recent comparisons of AIs with the most widely used oestrogen receptor blocking drug tamoxifen indicate that, in general, AIs result in increased response rates and greater durations of response. Here, we summarize data supporting the difference between the two types of treatment and attempt to account for the underlying mechanisms that favour AIs.
CitationEndocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. 2004, 6 (6):269-74 Breast Cancer Res.
JournalBreast Cancer Research
- Aromatase inhibitors and breast cancer.
- Authors: Miller WR
- Issue date: 2006 Mar
- Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
- Authors: Berry J
- Issue date: 2005 Nov
- Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
- Authors: Robertson JF
- Issue date: 2004 Dec
- Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
- Authors: Sainsbury R
- Issue date: 2004 May 4